glyburide has been researched along with c-peptide in 145 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 53 (36.55) | 18.7374 |
| 1990's | 56 (38.62) | 18.2507 |
| 2000's | 26 (17.93) | 29.6817 |
| 2010's | 10 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brändle, J; Irsigler, K; Ogris, E; Regal, H; Steinhardt, T; Zdolsek, I | 1 |
| Dudczak, R; Waldhäusl, W | 1 |
| Berchtold, P; Berger, M; Grüneklee, D; Schneider-Schultes, B; Zimmermann, H | 1 |
| Beischer, B; Beischer, W; Feilen, K; Keller, L; Maas, M; Pfeiffer, EF; Raptis, S | 1 |
| Beischer, B; Beischer, W; Keller, L; Kerner, W; Pfeiffer, EF; Raptis, S | 1 |
| Beischer, W; Heinze, E; Keller, L; Kerner, W; Pfeiffer, EF; Raptis, S | 1 |
| Beischer, W; Keller, L; Kerner, W; Pfeiffer, EF; Raptis, S | 1 |
| Andrews, WJ; Boreham, C; Boyd, K; Hadden, DR; Rogers, C | 1 |
| Lahti, J; Niskanen, L; Uusitupa, M | 1 |
| Friedberg, SJ; Pugh, JA; Ramirez, G; Sawyer, J; Tuley, M; Wagner, ML | 1 |
| Bird, DM; Cameron, DP; Ma, A; McIntyre, HD; Patterson, CA | 1 |
| Buscema, M; Italia, S; Mazzarino, S; Rabuazzo, AM; Sangiorgio, L; Squatrito, S; Trischitta, V; Vigneri, R | 1 |
| Birkeland, KI; Chatzipanagiotou, F; Hanssen, KF; Vaaler, S | 1 |
| Bingham, P; Garrison, C; Hart, J; McDaniel, P; Riddle, M | 1 |
| Buckley, GC; Jenkins, AL; Jenkins, DJ; Josse, RG; Vuksan, V; Wolever, TM; Wong, GS | 1 |
| Brodows, RG | 1 |
| Hermann, LS; Karlsson, JE; Sjöstrand, A | 1 |
| Andrews, WJ; Boreham, C; Boyd, K; Hadden, DR | 1 |
| Mulder, H; Schopman, W; van der Lely, AJ | 1 |
| Huupponen, R; Karvonen, I; Rytömaa, K; Sotaniemi, EA; Vierimaa, E; Vuoti, MJ | 1 |
| O'Meara, NM; Polonsky, KS; Shapiro, ET; Van Cauter, E | 1 |
| Defoin, R; Haefelfinger, P; Hartmann, D; Heinz, G; Komjati, M; Korn, A; Waldhäusl, WK | 1 |
| Beck-Nielsen, H; Binder, C; Butzer, P; Damsgaard, EM; Faber, OK; Froland, F; Hjollund, E; Lindskov, HO; Melander, A; Pedersen, O | 1 |
| Del Prato, S; Duner, E; Iavicoli, M; Lisato, G; Maifreni, L; Riccio, A; Tiengo, A; Vigili de Kreutzenberg, S | 1 |
| Reckless, JP; Simpson, HC; Stirling, CA; Sturley, R | 1 |
| Alford, FP; Best, JD; Crock, PA; Pestell, RG; Ward, GM | 1 |
| Carter, JN; Hooper, MJ; Lewitt, MS; Marel, GM; Rennie, GC; Yu, VK; Yue, DK | 1 |
| Beebe, C; Given, BD; Hirsch, L; Polonsky, KS; Rubenstein, AH; Shapiro, ET; Tillil, H; Van Cauter, E | 1 |
| Borzi, V; Italia, S; Mazzarino, S; Squatrito, S; Tribulato, A; Trischitta, V; Vigneri, R | 1 |
| Avico, U; Federzoni, G; Pacifici, R; Pichini, S; Pini, LA; Sternieri, E; Zuccaro, P | 1 |
| Haushofer, A; Lingg, G | 1 |
| Bouma, DJ; Hart, JS; Phillipson, BE; Riddle, MC; Youker, G | 1 |
| van Koetsveld, PM; Verschoor, L; Weber, RF; Weeks, L; Wolffenbuttel, BH | 1 |
| Huupponen, R | 1 |
| Augustin-Pascalis, I; Mirouze, J; Orsetti, A; Richard, JL; Rodier, M | 1 |
| Ketelslegers, JM; Lambert, AE; Mauerhoff, T | 1 |
| Beastall, GH; Buchanan, KD; Omile, C; Paterson, KR; Semple, CG | 1 |
| Klujko, J; Kühnle, HF; Reiter, J; Schmidt, FH | 1 |
| Castellino, P; DeFronzo, RA; Delprato, S; Groop, L; Simonson, DC | 1 |
| Jaminet, C; Lefebvre, PJ; Luyckx, AS; Scheen, AJ | 1 |
| Griego, G; Mitchell, WJ; Schade, DS | 1 |
| Borisova, AM; Kirilov, G; Koev, D | 1 |
| Berger, M; Kemmer, FW; Tacken, M | 1 |
| DeFronzo, RA; Groop, L; Groop, PH; Luzi, L; Melander, A; Ratheiser, K; Simonson, DC | 1 |
| Lundershausen, R; Orban, S; Panzram, G; Pissarek, D | 1 |
| Peacock, I; Selby, C; Tattersall, RB; Watts, R | 1 |
| Abraira, C; Lawrence, AM; Reich, A | 1 |
| Antal, EJ; Gillespie, WR; Phillips, JP; Veng-Pedersen, P | 1 |
| Lockwood, D; Nair, KS; Welle, S | 1 |
| Galione, A; Hopps, V; Sorrentino, MC; Vaccaro, F; Vetri, P; Woodrow, ME | 1 |
| Andersen, PH; Beck-Nielsen, H; Hother-Nielsen, O; Pedersen, O; Schmitz, O | 1 |
| Groop, L; Harno, K; Nikkilä, EA; Pelkonen, R; Tolppanen, EM | 1 |
| Falko, JM; Osei, K | 2 |
| Burke, BJ | 1 |
| Lardinois, CK; Liu, GC; Reaven, GM | 1 |
| Assal, JP; Hahn, C; Kuntschen, F; Pernet, A; Renold, AE; Trimble, ER | 1 |
| Groop, L; Kyllästinen, M | 1 |
| Fyhrqvist, F; Groop, L; Groop, PH; Melander, A; Tolppanen, EM; Tötterman, KJ; Wåhlin-Boll, E | 1 |
| Althoff, PH; Rosak, C; Schmidt, FH; Schöffling, K; Schwarz, O | 1 |
| Burnett, MA; Davies, EG; Harris, EA; Hosker, JP; Turner, RC | 1 |
| Ayanoglu, G; Badian, M; Witte, PU | 1 |
| Haupt, E; Putschky, F; Schöffling, K; Zoltobrocki, M | 1 |
| Groop, L; Harno, K; Tolppanen, EM | 1 |
| Peacock, I; Tattersall, RB | 1 |
| Ahrén, B; Scherstén, B | 1 |
| Burke, BJ; Hartog, M; Waterfield, MR | 1 |
| Falko, JM; O'Dorisio, TM; Osei, K | 1 |
| Kuzuya, K | 1 |
| Burke, BJ; Sherriff, RJ | 1 |
| Golding, PR; Goodall, P; Harrop, JS; Ingle, AR; Leveau, VM; Steele, GA | 1 |
| Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW | 1 |
| Adamson, U; Arner, P; Bolinder, J; Landstedt-Hallin, L; Lins, PE | 1 |
| Appel, S; Hitzenberger, G; Kalafsky, G; Kallay, Z; Kutz, K; Rüfenacht, T; Tetzloff, W | 1 |
| Abiru, N; Akazawa, S; Ishibasi, M; Kawasaki, E; Matsumoto, K; Matsuo, H; Uotani, S; Yamamoto, H; Yamasaki, H; Yano, M | 1 |
| Bitzén, PO; Hermann, LS; Kjellström, T; Lindgärde, F; Melander, A; Scherstén, B | 1 |
| Antal, EJ; Jaber, LA; Slaughter, RL; Welshman, IR | 2 |
| Beljic, T; Miric, M | 1 |
| Tayek, JA | 1 |
| Acosta, AM; Arteaga, A; Borkosky, M; Jiménez, M; Klaassen, J; Maiz, A; Velasco, N | 1 |
| Base, J; Kazdová, L; Kohout, M; Pelikánová, T; Válek, J | 1 |
| Balázsi, I; Hargitai, G; Takács, J | 1 |
| Abraira, C; Agrawal, L; Lawrence, AM; Murphy, JC; Soneru, IL | 1 |
| Abourizk, NN; Lyons, RW; Madden, GM | 1 |
| Ditzler, TM; Gumbiner, B; Henry, RR; Joyce, M; Murata, C; Song, YM; Suh, KI | 1 |
| Davidson, MB; Peters, AL | 1 |
| Hara, T; Hotta, N; Koh, N; Nakamura, J; Sakakibara, F; Takeuchi, N | 1 |
| Clauson, P; Efendic, S; Karlander, S; Steen, L | 1 |
| Antal, EJ; Jaber, LA; Welshman, IR | 1 |
| Birkenholz, M; Kabadi, M; Kabadi, UM; McCoy, S | 1 |
| Duarte, AL; Malerbi, DA; Paiva, ES; Wajchenberg, BL | 1 |
| Dills, DG; Schneider, J | 1 |
| Clark, HE; Matthews, DR | 1 |
| Herz, M; Massi-Benedetti, M; Pfeiffer, C | 1 |
| Menheere, PP; Nieuwenhuijzen Kruseman, AC; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH | 1 |
| Condorelli, L; Cordaro, G; Grasso, G; Lunetta, M; Rabuazzo, MA; Sangiorgio, L | 1 |
| Antonucci, TK; Driscoll, JH; Faja, BW; Ghazzi, MN; Huang, SM; Perez, JE; Whitcomb, RW | 1 |
| Clark, WS; Steen, MT; Umpierrez, GE | 1 |
| Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Santucci, A | 1 |
| Luzi, L; Pozza, G | 1 |
| Hwang, DL; Ishay, JS; Lev-Ran, A; Pertsis, V; Weissglas, L; Yerushalmy, Y | 1 |
| Bungert, S; Gudat, U; Heinemann, L; Kemmer, F | 1 |
| Heikkilä, M; Nikkilä, K; Ryysy, L; Tulokas, T; Vanamo, R; Yki-Järvinen, H | 1 |
| Bak, MI; Czyzyk, A; Dworak, A; Zapecka-Dubno, B | 1 |
| Huang, WC; Lebovitz, H; Marbury, T; Strange, P | 1 |
| Coppini, A; Erle, G; Lora, L; Lovise, S; Marchetti, P; Merante, D; Stocchiero, C | 1 |
| Adamson, U; Landstedt-Hallin, L; Lins, PE | 1 |
| Dimitriadis, G; Draeger, KE; Hatziagelaki, E; Pfeiffer, C; Raptis, AE; Raptis, SA | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Ehara, M; Morii, T; Sasaki, A; Sasakuma, F; Shimizu, T; Wada, H | 1 |
| Aida, K; Ikeda, M; Kodama, Y; Onaya, T; Tawata, M | 1 |
| Fonseca, V; Foyt, HL; Shen, K; Whitcomb, R | 1 |
| Banerji, MA; Chaiken, RL; Harrington, P; Hirsch, S; Lebovitz, HE; McFarlane, SI | 1 |
| Efendic, S; Kindmark, H; Pigon, J | 1 |
| Dunning, BE; Foley, JE; Gatlin, MR; Haas, SJ; Hollander, PA; Schwartz, SL; Zheng, H | 1 |
| Elisaf, M; Ioannidis, I; Karabina, SA; Karagiannacos, P; Katsilambros, N; Perrea, D; Skrapari, I; Tselepis, AD | 1 |
| Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ | 1 |
| Haupt, E; Rosak, C; Walter, T; Werner, J | 1 |
| Arranz, C; Cabrera-Rode, E; De Leiva, AD; Diaz-Horta, O; Dimario, U; Licea, M; Martin, JM; Molina, G; Perich, P; Puig-Domingo, M; Tiberti, C | 1 |
| Bavirti, S; Tayek, JA | 1 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Henricsson, M; Lager, I; Orn, T; Steen, L; Sundkvist, G; Westermark, G; Westermark, P | 1 |
| Carr, RD; Degn, KB; Gall, MA; Rizza, RA; Schmitz, O; Thomsen, MK; Veldhuis, JD; Østergård, T | 1 |
| Anderson, DM; Barnett, AH; Morgan, R; Owens, DR; Shelley, S | 1 |
| James, R; Kerenyi, Z; Samer, H; Stewart, M; Yan, Y | 1 |
| Guevara, M; Guevara-Aguirre, J; Mihic, M; Modi, P; Saavedra, J | 1 |
| Evans, ML; Fan, X; Flanagan, DE; Jacob, RJ; Keshavarz, T; McCrimmon, RJ; McNay, EC; Sherwin, RS | 1 |
| Brunetti, P; Gori, M; Pagano, G; Perriello, G; Turco, C | 1 |
| Cryer, PE; Fender, AB; Gerich, JE; Gosmanov, NR; Meyer, C; Nihalani, A; Sinkin, JC; Szoke, E | 1 |
| Groop, LC; Honkanen, EH; Isomaa, B; Sarelin, L; Tuomi, T | 1 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Holberg, MA; Kirksaether, N; Lager, I; Orn, T; Steen, L; Sundkvist, G | 1 |
| El-Ouaghlidi, A; Foley, J; Holmes, D; Holst, JJ; Nauck, MA; Rehring, E; Schweizer, A | 1 |
| Bellatreccia, A; Comaschi, M; Demicheli, A; Di Pietro, C; Mariz, S | 1 |
| Kim, GH; Kim, MS; Kim, SY; Lee, DW; Lee, DY; Yoo, HW | 1 |
| Guo, WL; Huang, CY; Lee, HC; Lee, YJ; Lin, CL; Lo, FS; Ting, WH | 1 |
| Aguilera, E; Fasano, CJ; Heard, K; O'Malley, GF; Rowden, AK | 1 |
| Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Lager, I; Orn, T; Steen, L | 1 |
| Ročić, B; Ročić, P; Vučić Lovrenčić, M; Weber, D; Znaor, A | 1 |
| Brooks-Worrell, BM; Palmer, JP | 1 |
| Caritis, SN; Hebert, MF | 1 |
| Asadi, A; Bruin, JE; Erener, S; Hu, X; Johnson, JD; Kieffer, TJ; Kurata, HT; Lynn, FC; Piret, JM; Rezania, A; Vela, J | 1 |
| Drain, P; Luppi, P | 1 |
| Davis, SN; Joy, NG; Tate, DB | 1 |
| Carvalho, D; Correia, C; Costa, C; Costa, M; Fontoura, M; Freitas, P; Lau, E; Nogueira, C; Saavedra, A | 1 |
| Barbetti, F; Bonfanti, R; Cerutti, F; Confetto, S; Iafusco, D; Ignaccolo, G; Maffeis, C; Marigliano, M; Ortolani, F; Piccinno, E; Rabbone, I; Zanfardino, A | 1 |
4 review(s) available for glyburide and c-peptide
| Article | Year |
|---|---|
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; MEDLINE; Meta-Analysis as Topic; Middle Aged; Periodicals as Topic; Sulfonylurea Compounds; Tolazamide; Treatment Outcome; United States | 1992 |
Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Glucose; Glyburide; Humans; Insulin; Insulin Secretion; Islets of Langerhans | 1990 |
[Effects and limitations of treatment of diabetes. On insulin secretory capacity (author's transl)].
Topics: C-Peptide; Diabetes Mellitus; Glyburide; Humans; Insulin; Insulin Secretion | 1980 |
Glibenclamide: an old drug with a novel mechanism of action?
Topics: Adipose Tissue; C-Peptide; Central Nervous System; Diabetes Mellitus, Type 2; Glyburide; Heart; Humans; Hypoglycemic Agents; Islets of Langerhans; Liver; Muscle, Skeletal; Potassium Channels | 1997 |
88 trial(s) available for glyburide and c-peptide
| Article | Year |
|---|---|
[Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl)].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Evaluation Studies as Topic; Glyburide; Humans; Placebos; Sulfonylurea Compounds | 1979 |
Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Insulin Resistance; Insulin Secretion; Metabolic Clearance Rate; Metformin; Middle Aged; Radioisotope Dilution Technique; Tritium | 1992 |
Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glyburide; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Prospective Studies; Recombinant Proteins; Treatment Failure; Triglycerides | 1992 |
Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis.
Topics: Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; MEDLINE; Meta-Analysis as Topic; Middle Aged; Periodicals as Topic; Sulfonylurea Compounds; Tolazamide; Treatment Outcome; United States | 1992 |
Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Kinetics; Middle Aged; Time Factors | 1992 |
Comparison of combined therapies in treatment of secondary failure to glyburide.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fasting; Glyburide; Glycated Hemoglobin; Humans; Insulin, Isophane; Metformin; Middle Aged; Obesity | 1992 |
Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
Topics: Adult; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipoproteins; Obesity; Triglycerides | 1992 |
Benefits and risks with glyburide and glipizide in elderly NIDDM patients.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Eating; Fasting; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Male | 1992 |
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Insulin Secretion; Lipids; Lipoproteins; Male; Metformin; Middle Aged; Prospective Studies; Triglycerides | 1991 |
Insulin and sulphonylurea in the therapy of type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Metformin; Middle Aged; Placebos; Random Allocation; Sulfonylurea Compounds | 1990 |
Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide; Drug Interactions; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Piroxicam; Random Allocation; Single-Blind Method | 1990 |
Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.
Topics: Administration, Oral; C-Peptide; Circadian Rhythm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Glucose; Glyburide; Humans; Injections; Insulin; Insulin Secretion; Insulin, Long-Acting; Liver; Male; Middle Aged; Sulfonylurea Compounds | 1990 |
Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol Esters; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipoproteins; Male; Middle Aged; Sulfonylurea Compounds | 1990 |
Fenfluramine increases insulin action in patients with NIDDM.
Topics: Adult; Aged; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenfluramine; Glyburide; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Reference Values | 1989 |
Effects of combined insulin-sulfonylurea therapy in type II patients.
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Insulin; Male | 1989 |
Influence of antacids on the bioavailability of glibenclamide.
Topics: Adult; Antacids; Biological Availability; Blood Glucose; C-Peptide; Colorimetry; Female; Glyburide; Humans; Insulin; Male | 1989 |
[Clinical study comparing the effectiveness and tolerance of 2 current and one new glibenclamide formulation].
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glyburide; Glycated Hemoglobin; Humans; Male; Middle Aged; Prospective Studies | 1989 |
Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fasting; Glucagon; Glyburide; Humans; Insulin, Isophane; Middle Aged; Random Allocation | 1989 |
A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy.
Topics: Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Insulin; Islets of Langerhans; Male; Middle Aged; Random Allocation; Tolbutamide | 1989 |
Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Topics: Blood Glucose; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glyburide; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Triglycerides | 1986 |
Effect of oral verapamil on glibenclamide stimulated insulin secretion.
Topics: Adult; C-Peptide; Glucagon; Glucose; Glyburide; Humans; Hypoglycemia; Insulin; Insulin Secretion; Male; Verapamil | 1986 |
[Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Insulin Infusion Systems; Male; Middle Aged | 1986 |
Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Compounding; Female; Glyburide; Humans; Insulin; Kinetics; Male; Methods; Middle Aged; Random Allocation | 1987 |
Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Random Allocation; Receptor, Insulin | 1987 |
[Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Male; Middle Aged | 1987 |
Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Male; Metformin; Middle Aged; Time Factors | 1987 |
Combined glyburide and insulin therapy in type II diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evaluation Studies as Topic; Glyburide; Glycosuria; Humans; Insulin; Male; Middle Aged | 1987 |
Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone.
Topics: Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Lipids; Male; Middle Aged | 1985 |
Sulphonylurea and insulin: combined treatment in type 1 (insulin-dependent) diabetes.
Topics: C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glyburide; Humans; Insulin | 1985 |
Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Topics: Blood Glucose; Blood Proteins; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipids; Lipoproteins; Male; Middle Aged; Placebos | 1985 |
Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Male | 1985 |
Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Erythrocytes; Female; Gastric Inhibitory Polypeptide; Glipizide; Glucagon; Glyburide; Glycosuria; Humans; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Random Allocation; Sulfonylurea Compounds | 1985 |
[Combined treatment of type-2 diabetics with insulin and glibenclamide after secondary drug failure. Double-blind, insulin-placebo-controlled crossover study].
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hydroxybutyrates; Insulin; Male; Middle Aged; Time Factors | 1985 |
Bioavailability and pharmacodynamics of a sustained-release glibenclamide product (Deroctyl) in comparison to a standard tablet formulation (Euglucon, Daonil).
Topics: Adult; Biological Availability; Blood Glucose; C-Peptide; Delayed-Action Preparations; Glyburide; Humans; Insulin; Male; Middle Aged; Tablets; Time Factors | 1983 |
[Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
Topics: Adult; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Insulin; Male; Middle Aged; Random Allocation | 1984 |
The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Male; Middle Aged; Random Allocation | 1984 |
The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
Topics: Adult; Aged; Attitude to Health; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prospective Studies; Random Allocation; Tablets | 1984 |
Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide.
Topics: Adult; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Glyburide; Humans; Insulin; Male; Random Allocation | 1984 |
Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Glucose Tolerance Test; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Time Factors | 1984 |
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Failure; Triglycerides | 1995 |
Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin, Isophane; Middle Aged; Time Factors; Treatment Failure; Triglycerides | 1995 |
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Glyburide; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Lovastatin; Placebos; Simvastatin; Tolbutamide | 1995 |
Insulin response after treatment depends on fasting plasma glucose level in NIDDM.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged | 1994 |
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Lipids; Male; Metformin; Middle Aged | 1994 |
Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients.
Topics: Adult; Blood Glucose; Blood Pressure; C-Peptide; Chlorpropamide; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Echocardiography, Doppler; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Male; Middle Aged; Reference Values; Triglycerides; Ventricular Function, Left | 1994 |
Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fats, Unsaturated; Fatty Acids, Omega-3; Fish Oils; Glyburide; Humans; Insulin; Kinetics; Male; Middle Aged; Obesity; Triglycerides | 1993 |
Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Fasting; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin, Long-Acting; Male; Middle Aged; Recombinant Proteins; Time Factors | 1993 |
An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM.
Topics: Biomarkers; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Energy Intake; Enzyme Inhibitors; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inpatients; Insulin; Middle Aged; Regression Analysis; Retrospective Studies; Sulfonylurea Compounds; Tolbutamide | 1996 |
Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Topics: Aged; Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin, Isophane; Insulin, Regular, Pork; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Failure; Triglycerides | 1996 |
Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aging; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glyburide; Half-Life; Humans; Insulin; Male; Middle Aged; Multivariate Analysis | 1996 |
More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Glucagon; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Triglycerides | 1995 |
Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1996 |
The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Clamp Technique; Glyburide; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Placebos; Sulfonylurea Compounds | 1996 |
The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise; Female; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1996 |
Comparison of different insulin regimens in elderly patients with NIDDM.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Fructosamine; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Lipids; Lipoprotein(a); Male; Netherlands; Triglycerides | 1996 |
[Comparative study of the efficiency of ultralente insulin and NPH insulin combined with sulfonylurea in type 2 diabetes patients with secondary tolerance to sulfonylurea. Possible selection criteria].
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Eating; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Insulin, Long-Acting; Male; Middle Aged; Treatment Outcome | 1996 |
Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Topics: Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Confidence Intervals; Diabetes Mellitus, Type 2; Echocardiography; Female; Glyburide; Glycated Hemoglobin; Heart; Heart Function Tests; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Stroke Volume; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Troglitazone | 1997 |
Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
Topics: Adult; Black or African American; Black People; Blood Glucose; C-Peptide; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diet, Diabetic; Female; Georgia; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Obesity; Recurrence | 1997 |
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
Topics: Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Metformin; Middle Aged; Regression Analysis; Sex Characteristics | 1997 |
The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exercise; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Lactic Acid; Middle Aged | 1998 |
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Topics: Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Middle Aged; Weight Gain | 1999 |
Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Topics: Adult; Amyloid; Blood Glucose; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Male; Metformin | 1999 |
Repaglinide versus glyburide: a one-year comparison trial.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Piperidines; Prospective Studies; Triglycerides; United States; United States Food and Drug Administration | 1999 |
A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Topics: Blood Glucose; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Time Factors | 1999 |
Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Double-Blind Method; Fasting; Food; Glyburide; Humans; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged; Placebos; Sulfonylurea Compounds | 1999 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Lipoproteins, HDL; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Topics: Aged; Area Under Curve; Blood Glucose; C-Peptide; Cyclohexanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Nateglinide; Phenylalanine; Placebos; Postprandial Period; Proinsulin; Single-Blind Method; Time Factors | 2001 |
Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
Topics: Adult; Area Under Curve; Blood Glucose; C-Peptide; Cholesterol; Chylomicrons; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glyburide; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Lipoproteins, VLDL; Middle Aged; Postprandial Period; Triglycerides | 2001 |
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Double-Blind Method; Female; Forearm; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vasodilation | 2002 |
The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Topics: Acarbose; Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Food; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kinetics; Male; Placebos | 2002 |
Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.
Topics: Autoantibodies; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glutamate Decarboxylase; Glyburide; Humans; Hypoglycemic Agents; Islets of Langerhans; Isoenzymes | 2002 |
Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Epinephrine; Fasting; Female; Glucose; Glucose Tolerance Test; Glyburide; Hormones; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Middle Aged; Oxidation-Reduction | 2003 |
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.
Topics: Adult; Aged; Amyloid; Blood Glucose; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Middle Aged; Proinsulin; Quality of Life | 2003 |
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
Topics: Blood Glucose; C-Peptide; Carbamates; Diabetes Mellitus, Type 1; Fatty Acids, Nonesterified; Glucagon; Glucose Clamp Technique; Glyburide; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin; Piperidines; Placebos; Potassium Channel Blockers; Somatostatin | 2004 |
A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2004 |
Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2004 |
Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Prospective Studies; Statistics, Nonparametric | 2004 |
Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Food; Glyburide; Glycated Hemoglobin; History, 18th Century; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Prospective Studies | 2004 |
Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia.
Topics: Adult; Blood Glucose; C-Peptide; Epinephrine; Female; Glucose; Glyburide; Hormones; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Kinetics; Male; Sulfonylurea Compounds | 2006 |
Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Exercise Test; Female; Glucagon; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Nateglinide; Phenylalanine; Postprandial Period | 2006 |
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Follow-Up Studies; Glucagon; Glyburide; Glycated Hemoglobin; Health Status Indicators; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Insulin, Long-Acting; Lipids; Male; Middle Aged; Proinsulin; Quality of Life | 2008 |
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
Topics: Adamantane; Adult; Algorithms; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glyburide; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Nitriles; Pyrrolidines; Vildagliptin | 2007 |
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Safety; Thiazolidinediones | 2007 |
Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Middle Aged | 2010 |
Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Creatine; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period | 2011 |
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.
Topics: Adult; Aged; Autoantibodies; Autoimmunity; C-Peptide; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Immunosuppression Therapy; Interferon-gamma; Interleukin-12; Islets of Langerhans; Male; Middle Aged; PPAR gamma; Rosiglitazone; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Thiazolidinediones | 2013 |
Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucagon; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Leptin; Male; Pancreatic Polypeptide; Single-Blind Method; Sulfonylurea Compounds | 2015 |
54 other study(ies) available for glyburide and c-peptide
| Article | Year |
|---|---|
[Clinical significance of the radioimmunological determination of C-peptide (author's transl)].
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus; Fasting; Glyburide; Humans; Insulin; Middle Aged; Peptides; Protein Binding; Radioimmunoassay | 1979 |
[Attempted suicide using glibenclamide:course of glucose, insulin, glibenclamide and C-peptide blood levels].
Topics: Blood Glucose; C-Peptide; Glyburide; Humans; Insulin; Male; Middle Aged; Suicide, Attempted | 1977 |
[Human C-peptide. Part III: dynamics of secretion of beta-cells in adult diabetics following glibenclamide-glucose i.v. (human C-peptide III) (author's transl)].
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus; Female; Glucose; Glyburide; Humans; Injections, Intravenous; Insulin; Islets of Langerhans; Male; Middle Aged; Peptides; Tablets | 1978 |
Insulin therapy in relation to circulating C-peptide levels.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged; Peptides; Radioimmunoassay | 1978 |
Human C-peptide. Part II: Clinical studies.
Topics: C-Peptide; Chromatography, Gel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose; Glyburide; Humans; Insulin; Pancreatic Hormones; Peptides | 1976 |
[C-peptide determination as a parameter for oral diabetes therapy].
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus; Glyburide; Humans; Insulin; Peptides | 1976 |
Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects.
Topics: Antihypertensive Agents; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypertension; Infusions, Intravenous; Insulin; Male; Metformin; Middle Aged; Regression Analysis | 1992 |
Beneficial effect of a low glycaemic index diet in type 2 diabetes.
Topics: Aged; Biomarkers; Blood Glucose; C-Peptide; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Diet, Diabetic; Dietary Carbohydrates; Energy Intake; Female; Fructosamine; Glyburide; Hexosamines; Humans; Insulin; Male; Triglycerides; Urea | 1992 |
Correction of fasting hyperglycaemia with insulin or sulphonylurea lowers fasting ketone levels, but does not alter resting or post-glucose energy expenditure in non insulin dependent diabetes. Differences between the OGTT and the glucose clamp.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Energy Metabolism; Fasting; Female; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Glyburide; Humans; Hyperglycemia; Insulin; Ketone Bodies; Liver; Male; Middle Aged | 1991 |
Extrapancreatic insulin effect of glibenclamide.
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Food; Glyburide; Humans; Insulin; Male; Middle Aged; Radioimmunoassay | 1991 |
Acute actions of sulfonylurea drugs during long-term treatment of NIDDM.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds; Time Factors | 1990 |
Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glyburide; Humans; Hyperglycemia; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Middle Aged | 1989 |
Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Islets of Langerhans; Male; Middle Aged | 1989 |
The effect of guar gum on the acute metabolic response to glyburide.
Topics: Adult; Blood Glucose; C-Peptide; Dietary Fiber; Female; Galactans; Glyburide; Humans; Insulin; Mannans; Plant Gums | 1986 |
[Secondary failure of oral antidiabetics. Value of intravenous insulin infusions].
Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Infusion Systems; Male; Metformin; Middle Aged | 1986 |
Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Liver; Male; Time Factors | 1987 |
[Possibility of transferring patients with type-II diabetes mellitus treated with small doses of sulfonylurea preparations to diet therapy].
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucagon; Glyburide; Humans; Insulin; Insulin Secretion; Male; Middle Aged; Sulfonylurea Compounds | 1987 |
Mechanism of exercise-induced hypoglycemia during sulfonylurea treatment.
Topics: Adult; C-Peptide; Glucagon; Glyburide; Humans; Hypoglycemia; Insulin; Kinetics; Lactates; Lactic Acid; Male; Physical Exertion | 1987 |
Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glipizide; Glucagon; Glucose; Glyburide; Humans; Hyperglycemia; Insulin; Insulin Secretion; Kinetics; Liver; Sulfonylurea Compounds | 1987 |
A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glyburide; Humans | 1988 |
Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
Topics: Blood Glucose; Blood Urea Nitrogen; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Metabolism; Epinephrine; Female; Glucagon; Glyburide; Glycosuria; Humans; Insulin; Male; Middle Aged; Norepinephrine; Obesity | 1988 |
Glybenclamide and cyclosporine A: an interaction on glucose metabolism.
Topics: Animals; C-Peptide; Cyclosporins; Drug Interactions; Glucagon; Glucose; Glyburide; Glycogen; Insulin; Rats | 1988 |
In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Male; Obesity; Reference Values | 1988 |
Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1985 |
Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone.
Topics: Adult; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Energy Intake; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Insulin; Insulin Secretion; Liver; Male; Metabolic Clearance Rate; Middle Aged | 1985 |
Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Glucose; Glyburide; Humans; Hypoglycemic Agents; Infusions, Parenteral; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1985 |
Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
Topics: Aged; Blood Glucose; C-Peptide; Chlorpropamide; Diabetes Mellitus, Type 2; Glucose; Glyburide; Humans; Hyperglycemia; Insulin; Insulin Resistance; Islets of Langerhans; Middle Aged; Sulfonylurea Compounds | 1985 |
Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Food; Glipizide; Glyburide; Humans; Insulin; Liver Diseases; Liver Neoplasms; Sulfonylurea Compounds | 1984 |
Stimulation of residual insulin secretion by glibenclamide in insulin dependent diabetics.
Topics: Adolescent; Adult; C-Peptide; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; Insulin Secretion; Male | 1980 |
C-peptide suppression test and sulphonylurea-induced factitious hypoglycaemia.
Topics: Adult; C-Peptide; Diagnosis, Differential; Factitious Disorders; Glyburide; Humans; Hypoglycemia; Insulin; Insulinoma; Male; Pancreatic Neoplasms; Peptides | 1982 |
Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Half-Life; Humans; Insulin; Lipids; Male; Middle Aged | 1994 |
Low-dose oral glyburide reduces fasting blood glucose by decreasing hepatic glucose production in healthy volunteers without increasing carbohydrate oxidation.
Topics: Blood Glucose; C-Peptide; Calorimetry, Indirect; Fasting; Female; Glucose; Glucose Tolerance Test; Glyburide; Humans; Insulin; Kinetics; Leucine; Liver; Male; Oxidation-Reduction | 1995 |
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Male; Middle Aged; Obesity; Time Factors | 1993 |
[Non-insulin-dependent diabetics with secondary failure: insulin therapy at bedtime combined with glibenclamide].
Topics: Aged; Analysis of Variance; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Male; Middle Aged; Time Factors; Treatment Failure | 1993 |
[C-peptide levels in secondary sulfonylurea resistant diabetics].
Topics: Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Resistance; Female; Glucagon; Glyburide; Humans; Insulin; Male; Middle Aged; Sulfonylurea Compounds | 1993 |
Transient state of NIDDM in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Pentamidine; Proinsulin | 1993 |
Intracellular glucose metabolism after long term metabolic control with glyburide: improved glucose oxidation with unchanged glycogen synthase activity.
Topics: Blood Glucose; Body Composition; Body Mass Index; C-Peptide; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Glucose; Glucose Clamp Technique; Glyburide; Glycogen Synthase; Humans; Insulin; Male; Middle Aged; Muscles; Obesity; Oxidation-Reduction; Pyruvate Dehydrogenase Complex | 1993 |
Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Ketones; Male; Middle Aged; Polyuria; Prospective Studies; Retrospective Studies; Urination Disorders; Weight Loss | 1996 |
Metabolic effects of dietary sucrose and fructose in type II diabetic subjects.
Topics: Adult; Aged; Blood Glucose; Blood Proteins; Body Weight; C-Peptide; Chlorpropamide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Sucrose; Energy Intake; Female; Fructose; Glyburide; Glycated Serum Proteins; Glycoproteins; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Postprandial Period; Triglycerides | 1996 |
In most poorly controlled glyburide-treated type 2 diabetic patients drug withdrawal causes further increase in glycemia not accompanied by changes in insulin secretion.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged | 1998 |
Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epinephrine; Female; Glucagon; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Kinetics; Male; Middle Aged | 1999 |
Human anti-murine antibodies interfere with CPR assays performed with commercial kits.
Topics: Aged; Animals; Antibodies; Antibodies, Monoclonal; Artifacts; C-Peptide; Child, Preschool; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Mice; Proinsulin; Radioimmunoassay; Reagent Kits, Diagnostic; Reagent Strips; Reproducibility of Results | 2000 |
A type 2 diabetic patient with liver dysfunction due to human insulin.
Topics: Alanine Transaminase; Alkaline Phosphatase; Antibodies, Viral; Aspartate Aminotransferases; Bilirubin; C-Peptide; Diabetes Mellitus, Type 2; gamma-Glutamyltransferase; Glyburide; Hepatitis B Surface Antigens; Humans; Hypoglycemic Agents; Immunoglobulin M; Insulin; Insulin Antibodies; Ketone Bodies; L-Lactate Dehydrogenase; Liver Diseases; Lymphocyte Activation; Male; Middle Aged; Thirst | 2000 |
Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function.
Topics: Aged; Biomarkers; Black or African American; Black People; Blood Glucose; C-Peptide; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Middle Aged; New York City; Patient Education as Topic; Prospective Studies; Time Factors | 2001 |
Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction.
Topics: Adult; Blood Glucose; C-Peptide; Drug Synergism; Female; Gastric Inhibitory Polypeptide; Glucagon; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male | 2001 |
Hypothalamic ATP-sensitive K + channels play a key role in sensing hypoglycemia and triggering counterregulatory epinephrine and glucagon responses.
Topics: Animals; Blood Glucose; Brain; C-Peptide; Cerebral Ventricles; Glyburide; Infusions, Parenteral; Insulin; Male; Potassium Channels; Rats; Rats, Sprague-Dawley; Ventromedial Hypothalamic Nucleus | 2004 |
Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
Topics: Base Sequence; C-Peptide; Diabetes Mellitus; DNA Mutational Analysis; Female; Glyburide; Glycated Hemoglobin; Heterozygote; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Insulin; Korea; Mutation; Potassium Channels, Inwardly Rectifying; Sulfonylurea Compounds; Treatment Outcome | 2007 |
Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus.
Topics: Adolescent; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 1; DNA Mutational Analysis; Drug Therapy, Combination; Fasting; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Point Mutation; Potassium Channels, Inwardly Rectifying; Treatment Outcome | 2009 |
Quantitative insulin and C-peptide levels among ED patients with sulfonylurea-induced hypoglycemia-a prospective case series.
Topics: Aged; Aged, 80 and over; C-Peptide; Cross-Sectional Studies; Drug Overdose; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Prospective Studies; Sulfonylurea Compounds | 2010 |
A pharmacologic approach to the use of glyburide in pregnancy.
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Placenta; Pregnancy | 2013 |
Characterization of polyhormonal insulin-producing cells derived in vitro from human embryonic stem cells.
Topics: Adenosine Triphosphate; C-Peptide; Cell Differentiation; Embryonic Stem Cells; Endocrine Cells; Glucokinase; Glucose Transporter Type 1; Glyburide; Hormones; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; KATP Channels; Potassium Channels, Inwardly Rectifying; Sulfonylurea Receptors | 2014 |
Autocrine C-peptide mechanism underlying INS1 beta cell adaptation to oxidative stress.
Topics: Adaptation, Physiological; Animals; Apoptosis; Autocrine Communication; C-Peptide; Cell Line, Tumor; Diazoxide; Disease Models, Animal; Glucose; Glyburide; Hydrogen Peroxide; Hypoglycemic Agents; Insulin-Secreting Cells; Insulinoma; Oxidative Stress; Pancreatic Neoplasms; Potassium Chloride; Rats; Reactive Oxygen Species | 2014 |
Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Drug Substitution; Glyburide; Humans; Hypoglycemic Agents; Male; Mutation; Potassium Channels, Inwardly Rectifying; Sulfonylurea Compounds; Treatment Failure; Young Adult | 2015 |
Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Female; Glyburide; Humans; Hyperglycemia; Infant; Infant, Newborn; Insulin; Insulin Infusion Systems; Male; Monitoring, Physiologic; Sulfonylurea Compounds | 2016 |